Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00012038 · ClinicalTrials.gov registry record · Phase 1
Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors
A Phase 1 study, sponsored by New Approaches to Brain Tumor Therapy Consortium.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00012038: Completed Phase 1 study, sponsored by New Approaches to Brain Tumor Therapy Consortium.
NCT00012038 is a Phase 1 study that has completed, run by New Approaches to Brain Tumor Therapy Consortium. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00012038, a Phase 1 study, has completed, sponsored by New Approaches to Brain Tumor Therapy Consortium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of irofulven in treating patients who have progressive or recurrent astrocytoma, oligodendroglioma, or glioblastoma multiforme.
Interventions
- DRUG irofulven
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-07 |
| Est. Completion | 2003-10 |
| Phase | Phase 1 |
What the finished NCT00012038 record still lists
NCT00012038 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which irofulven is the first listed.
NCT00012038 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00012038 about?
NCT00012038 is a clinical study titled "Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of irofulven in treating patients who have progressive or recurrent astrocytoma, oligodendroglioma, or glioblastoma multiforme...
What is the current status of trial NCT00012038?
This trial is currently completed. It is a Phase 1 study. The study started on 2001-07. Estimated completion is 2003-10.
What interventions are being tested in trial NCT00012038?
The interventions under investigation include: irofulven (DRUG).
Who is sponsoring clinical trial NCT00012038?
This trial is sponsored by New Approaches to Brain Tumor Therapy Consortium, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia